Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Study Evaluates Sociodemographic Factors and Survival Outcomes for Patients with CLL/SLL
07/18/2023

Emry Lloyd

Emry Lloyd
Researchers analyzed whether sociodemographic characteristics influence the overall survival rate of Hispanic vs non-Hispanic patients with CLL/SLL
Researchers analyzed whether sociodemographic characteristics influence the overall survival rate of Hispanic vs non-Hispanic patients with CLL/SLL
Researchers analyzed whether...
07/18/2023
Journal of Clinical Pathways
Conference Coverage
Study Compares the Efficacy and Safety of Acalabrutinib vs Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia
07/07/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a study to compare two drugs for R/R CLL treatment safety: acalabrutinib and zanubrutinib.
Researchers conducted a study to compare two drugs for R/R CLL treatment safety: acalabrutinib and zanubrutinib.
Researchers conducted a study to...
07/07/2023
Journal of Clinical Pathways

Advertisement

Conference Coverage
Overall Survival Analysis of Patients with R/R LBCL Receiving Axicabtagene Ciloleucel vs Standard of Care Therapy: ZUMA-7 Study
06/27/2023

Grace Taylor

Grace Taylor
Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.
Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.
Jason Westin, MD, and colleagues...
06/27/2023
Journal of Clinical Pathways
Conference Coverage
Evaluation of a Medication Acquisition Program for Patient Access to Off-Label Treatment
06/21/2023

Emry Lloyd

Emry Lloyd
Researchers analyzed the success of their institution’s medication acquisition program for patients with cancer, including tracking clinical benefit.
Researchers analyzed the success of their institution’s medication acquisition program for patients with cancer, including tracking clinical benefit.
Researchers analyzed the success...
06/21/2023
Journal of Clinical Pathways
Dr Barb Kunz.
Videos
The Impact of Social Determinants of Health on Use of Germline Genetic Testing for Triple-Negative Breast Cancer
06/20/2023

Featuring Barb Kunz

Featuring Barb Kunz
Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Barb Kunz, the US Oncology...
06/20/2023
Journal of Clinical Pathways

Advertisement

Conference Coverage
Study Examines Real-World Outcomes of Novel Treatments for Diffuse Large B-Cell Lymphoma
06/14/2023

Emry Lloyd

Emry Lloyd
Researchers conducted a retrospective analysis to evaluate the outcomes of patients with R/R DLBCL treated with novel therapies, with a subanalysis of patients who received CAR T prior to novel therapies.
Researchers conducted a retrospective analysis to evaluate the outcomes of patients with R/R DLBCL treated with novel therapies, with a subanalysis of patients who received CAR T prior to novel therapies.
Researchers conducted a...
06/14/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Conference Coverage
Research Shows that Health Care Costs Vary Based on HIC Status in Patients With NSCLC
06/13/2023

Emry Lloyd

Emry Lloyd
In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.
In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.
In an abstract presented at ASCO...
06/13/2023
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-World Outcomes by Race in Patients with Chronic Lymphocytic Leukemia in the informCLL Registry Study
06/12/2023

Grace Taylor

Grace Taylor
Data from the informCLL clinical trial, presented at the 2023 ASCO Annual Meeting, analyzed the impact of access to novel therapies on clinical outcomes stratified by race in patients with CLL/SLL.
Data from the informCLL clinical trial, presented at the 2023 ASCO Annual Meeting, analyzed the impact of access to novel therapies on clinical outcomes stratified by race in patients with CLL/SLL.
Data from the informCLL clinical...
06/12/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use